Cardene I: Phase IV data

The open-label, U.S. Phase IV CLUE trial in 226 patients admitted to the emergency room with 2 SBP readings of >180 mmHg measured >=10 minutes apart showed that a significantly greater proportion of patients receiving Cardene I.V. achieved their TSBPR after 30 min vs. IV labetalol (91.7% vs. 82.5%, p=0.039). Adverse events were rare in both treatment groups. Data were presented at the American College of Emergency Physicians meeting in Las Vegas. ...